Anästhesiol Intensivmed Notfallmed Schmerzther 2017; 52(09): 630-639
DOI: 10.1055/s-0043-114676
Fortbildung
Georg Thieme Verlag KG Stuttgart · New York

Remifentanil up2date – Teil 2

Remifentanil up2date – Part 2
Stefan Bushuven
,
Sascha Kreuer
,
Peter Kranke
Further Information

Publication History

Publication Date:
08 September 2017 (online)

Zusammenfassung

Remifentanil wird seit 20 Jahren mit Erfolg in vielen Bereichen der Anästhesiologie eingesetzt. Im 1. Teil wurde die Substanz mit ihren pharmakologischen Charakteristika sowie ihren erwünschten und unerwünschten Wirkungen beschrieben. Der hier vorliegende 2. Teil befasst sich mit der Anwendung des Opioids bei speziellen Patientengruppen und in den verschiedenen anästhesiologisch betreuten Fachdisziplinen.

Abstract

Remifentanil is a short-acting opioid of high analgetic potency and superior controllability. It is widely used in day-case surgery, procedural sedation, for reduction of recovery-times and obstetrics and whenever excellent controllability of opioid effects is needed. Especially in combination with propofol it is used for target controlled infusion (TCI). The second part of the article shows the differences between groups of patients regarding the use of remifentanil.

Kernaussagen
  • Remifentanil ist mittlerweile seit 20 Jahren im klinischen Einsatz. Die pharmakokinetischen und pharmakodynamischen Eigenschaften zeichnen die gute Steuerbarkeit des Medikaments aus.

  • Vor allem die kurze kontextsensitive Eingriffszeit führt dazu, dass die Substanz in der Neonatologie, der Prozeduralsedierung, in der Elektrokrampftherapie und neuerdings in der Geburtshilfe unter entsprechenden Sicherheitsmaßnahmen eingesetzt wird.

  • In anderen Bereichen wie der Notfallmedizin und der Endoskopie konnte sich Remifentanil bisher nicht nachhaltig durchsetzen.

  • In der Versorgung von chronischen Schmerzpatienten und Patienten mit Abhängigkeiten kann es von großem Vorteil sein, muss jedoch teilweise sehr hoch dosiert werden.

  • Zu den Nachteilen des Pharmakons zählen typische Opioideffekte, wie Atemdepression, Bradykardien und Thoraxrigidität sowie die kontrovers diskutierte opioidinduzierte Hyperalgesie (OIH).

  • Remifentanil ist zusammen mit Propofol in der Hand des geübten Anästhesisten ein wertvolles und sicheres Medikament, das vor allem in der ambulanten Anästhesiologie „nahezu unverzichtbar“ ist.

  • Aus diesem Grund trifft die seit 2016 bestehende eingeschränkte Verfügbarkeit und Kontingentierung der Substanz in Deutschland vor allem diesen Zweig der Anästhesiologie hart.

 
  • Literatur

  • 1 Demirel N, Bas AY, Kavurt S. et al. Remifentanil analgesia during laser treatment for retinopathy of prematurity: a practical approach in neonatal intensive care unit. American journal of perinatology 2014; 31: 983-986 doi:10.1055/s-0034-1370348
  • 2 Sammartino M, Bocci MG, Ferro G. et al. Efficacy and safety of continuous intravenous infusion of remifentanil in preterm infants undergoing laser therapy in retinopathy of prematurity: clinical experience. Paediatric anaesthesia 2003; 13: 596-602
  • 3 Shin SH, Kim HS, Lee J. et al. A comparative study of two remifentanil doses for procedural pain in ventilated preterm infants: a randomized, controlled study*. Pediatric critical care medicine 2014; 15: 451-455 doi:10.1097/PCC.0000000000000123
  • 4 Lago P, Tiozzo C, Boccuzzo G. et al. Remifentanil for percutaneous intravenous central catheter placement in preterm infant: a randomized controlled trial. Paediatric anaesthesia 2008; 18: 736-744 doi:10.1111/j.1460-9592.2008.02636.x
  • 5 Welzing L, Kribs A, Huenseler C. et al. Remifentanil for INSURE in preterm infants: a pilot study for evaluation of efficacy and safety aspects. Acta paediatrica 2009; 98: 1416-1420 doi:10.1111/j.0803-5253.2009.01364.x
  • 6 Avino D, Zhang WH, De Ville A. et al. Remifentanil versus morphine-midazolam premedication on the quality of endotracheal intubation in neonates: a noninferiority randomized trial. Journal of pediatrics 2014; 164: 1032-1037 doi:10.1016/j.jpeds.2014.01.030
  • 7 Badiee Z, Vakiliamini M, Mohammadizadeh M. Remifentanil for endotracheal intubation in premature infants: A randomized controlled trial. Journal of research in pharmacy practice 2013; 2: 75-82 doi:10.4103/2279-042X.117387
  • 8 Penido MG, de Oliveira Silva DF, Tavares EC. et al. Propofol versus midazolam for intubating preterm neonates: a randomized controlled trial. Journal of perinatology 2011; 31: 356-360 doi:10.1038/jp.2010.135
  • 9 Pereira e Silva Y, Gomez RS, Marcatto Jde O, Maximo TA, Barbosa RF, Simões e Silva AC. Morphine versus remifentanil for intubating preterm neonates. Archives of disease in childhood Fetal and neonatal edition 2007; 92: F293-F294 doi:10.1136/adc.2006.105262
  • 10 e Silva YP. Gomez RS, Marcatto Jde O. et al. Early awakening and extubation with remifentanil in ventilated premature neonates. Paediatr Anaesth 2008; 18: 176-183 doi:10.1111/j.1460-9592.2007.02378.x
  • 11 Sammartino M, Garra R, Sbaraglia F. et al. Experience of remifentanil in extremely low-birth-weight babies undergoing laparotomy. Pediatrics and neonatology 2011; 52: 176-179 doi:10.1016/j.pedneo.2011.03.013
  • 12 De Kort EH, Hanff LM, Roofthooft D. et al. Insufficient sedation and severe side effects after fast administration of remifentanil during INSURE in preterm newborns. Neonatology 2017; 111: 172-176 doi:10.1159/000450536
  • 13 Kamata M, Tobias JD. Remifentanil: applications in neonates. Journal of anesthesia 2016; 30: 449-460 doi:10.1007/s00540-015-2134-5
  • 14 Marsh DF, Hodkinson B. Remifentanil in paediatric anaesthetic practice. Anaesthesia 2009; 64: 301-308 doi:10.1111/j.1365-2044.2008.05731.x
  • 15 GmbH & CoKG GSK. Fachinformationen Ultiva. In Webpage: Glaxo Smith Kline 2015. Im Internet: https://www.fachinfo.de/suche/fi/007585 Stand: Juli 2017
  • 16 Embryotox. Embryotox. 2013 Im Internet: http://www.embryotox.de Stand: Juli 2017
  • 17 Noskova P, Blaha J, Bakhouche H. et al. Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial. BMC anesthesiology 2015; 15: 38 doi:10.1186/s12871-015-0020-1
  • 18 Heesen M, Klohr S, Hofmann T. et al. Maternal and foetal effects of remifentanil for general anaesthesia in parturients undergoing caesarean section: a systematic review and meta-analysis. Acta anaesthesiologica Scandinavica 2013; 57: 29-36 doi:10.1111/j.1399-6576.2012.02723.x
  • 19 Van de Velde M. The use of remifentanil during general anesthesia for caesarean section. Current opinion in anaesthesiology 2016; 29: 257-260 doi:10.1097/ACO.0000000000000334
  • 20 Wasem S, Rifai M, Honig A. et al. Leser fragen – Experten antworten – Rapid-Sequence-Induction bei Sectio caesarea: Sollte standardmäßig ein Opioid gegeben werden?. Anästhesiol Intensivmed Notfallmed Schmerzther 2013; 48: 374-377 doi:10.1055/s-0033-1348999
  • 21 Alavi SM, Ghoreishi SM, Chitsazan M. et al. Patient-controlled analgesia after coronary bypass: Remifentanil or sufentanil?. Asian cardiovascular & thoracic annals 2013; 22: 694-699 doi:10.1177/0218492313507783
  • 22 Guggenberger H, Schroeder TH, Vonthein R. et al. Remifentanil or sufentanil for coronary surgery: comparison of postoperative respiratory impairment. European journal of anaesthesiology 2006; 23: 832-840 doi:10.1017/S0265021506000251
  • 23 Del Blanco Narciso BB, Jimeno Fernandez C, Almendral Garrote J. et al. Effects of remifentanil on the cardiac conduction system. Our experience in the study of remifentanil electrophysiological properties. Current pharmaceutical design 2014; 20: 5489-5496
  • 24 Tanguy M, Seguin P, Laviolle B. et al. Cerebral microdialysis effects of propofol versus midazolam in severe traumatic brain injury. Journal of neurotrauma 2012; 29: 1105-1110 doi:10.1089/neu.2011.1817
  • 25 Bernards CM, Knowlton SL, Schmidt DF. et al. Respiratory and sleep effects of remifentanil in volunteers with moderate obstructive sleep apnea. Anesthesiology 2009; 110: 41-49 doi:10.1097/ALN.0b013e318190b501
  • 26 Gruber EM, Tschernko EM. Anaesthesia and postoperative analgesia in older patients with chronic obstructive pulmonary disease: special considerations. Drugs & aging 2003; 20: 347-360
  • 27 Spieth PM, Guldner A, de Abreu MG. Chronic obstructive pulmonary disease. Current opinion in anaesthesiology 2012; 25: 24-29 doi:10.1097/ACO.0b013e32834dd269
  • 28 Rodgers A, Walker N, Schug S. et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. Bmj 2000; 321: 1493
  • 29 Burburan SM, Xisto DG, Rocco PR. Anaesthetic management in asthma. Minerva anestesiologica 2007; 73: 357-365
  • 30 Hohne C, Donaubauer B, Kaisers U. Opioide in der Anästhesie bei Leber- und Niereninsuffizienz. Der Anaesthesist 2004; 53: 291-303
  • 31 Dumont L, Picard V, Marti RA. et al. Use of remifentanil in a patient with chronic hepatic failure. British journal of anaesthesia 1998; 81: 265-267
  • 32 Vaja R. . Anaesthesia for patients with liver disease Contin Educ Anaesth Crit Care Pain 2010; 10: 15-19
  • 33 Djafarzadeh S, Vuda M, Takala J. et al. Effect of remifentanil on mitochondrial oxygen consumption of cultured human hepatocytes. PLoS One 2012; 7: e45195 doi:10.1371/journal.pone.0045195
  • 34 Pitsiu M, Wilmer A, Bodenham A. et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. British journal of anaesthesia 2004; 92: 493-503 doi:10.1093/bja/aeh086
  • 35 Dahaba AA, Oettl K, von Klobucar F. et al. End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. Canadian journal of anaesthesia 2002; 49: 369-374 doi:10.1007/BF03017324
  • 36 Roquilly A, Perbet S, Simonneau F. et al. Ammonia plasma concentration and prolonged infusion of remifentanil in patients with acute kidney injury. Minerva anestesiologica 2013; 79: 884-890
  • 37 Breen D, Wilmer A, Bodenham A. et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Critical care 2004; 8: R21-R30 doi:10.1186/cc2399
  • 38 Sclar DA. Remifentanil, fentanyl, or the combination in surgical procedures in the United States: predictors of use in patients with organ impairment or obesity. Clinical drug investigation 2015; 35: 53-59 doi:10.1007/s40261-014-0251-9
  • 39 Terashi T, Takehara A, Kuniyoshi T. et al. Remifentanil temporarily improves renal function in adult patients with chronic kidney disease undergoing orthopedic surgery. Journal of anesthesia 2013; 27: 340-345 doi:10.1007/s00540-012-1545-9
  • 40 Egan TD, Huizinga B, Gupta SK. et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-573
  • 41 Janmahasatian S, Duffull SB, Ash S. et al. Quantification of lean bodyweight. Clinical pharmacokinetics 2005; 44: 1051-1065 doi:10.2165/00003088-200544100-00004
  • 42 La Colla L, Albertin A, La Colla G. et al. Predictive performance of the “Minto” remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clinical pharmacokinetics 2010; 49: 131-139 doi:10.2165/11317690-000000000-00000
  • 43 Kontrimaviciute E, Sipylaite J, Aksionova D. et al. Comparison of different anesthetic regimens in patients undergoing laparoscopic adjustable gastric banding operations: a prospective randomized trial. Medicina 2012; 48: 613-618
  • 44 Bidgoli J, Delesalle S, De Hert SG. et al. A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient. European journal of anaesthesiology 2011; 28: 120-124 doi:10.1097/EJA.0b013e3283405048
  • 45 Bellamy MC, Margarson MP. Designing intelligent anesthesia for a changing patient demographic: a consensus statement to provide guidance for specialist and non-specialist anesthetists written by members of and endorsed by the Society for Obesity and Bariatric Anaesthesia (SOBA). Perioperative medicine 2013; 2: 12 doi:10.1186/2047-0525-2-12
  • 46 Schneemilch C. Neurologische Erkrankungen – Allgemeinanästhesie bei neurologischen Erkrankungen. Anästhesiol Intensivmed Notfallmed Schmerzther 2010; 45: 336-344 doi:10.1055/s-0030-1253568
  • 47 Wang JF, Xu XP, Yu XY. et al. Remifentanil requirement for inhibiting responses to tracheal intubation and skin incision is reduced in patients with Parkinsonʼs disease undergoing deep brain stimulator implantation. Journal of neurosurgical anesthesiology 2016; 28: 303-308 doi:10.1097/ANA.0000000000000229
  • 48 Salazar G, Motamed C. A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinsonʼs disease: two case reports. Journal of opioid management 2012; 8: 133-134
  • 49 Bohmdorfer W, Schwarzinger P, Binder S. et al. Vorübergehende Beseitigung des Tremors bei M. Parkinson durch Remifentanil während einer Kataraktoperation in Lokalanästhesie. Der Anaesthesist 2003; 52: 795-797 doi:10.1007/s00101-003-0522-y
  • 50 Wootton MA, Lockie J. Anaesthetic management of a child with a positive family history of malignant hyperthermia for posterior fossa surgery in the sitting position. Paediatric anaesthesia 2001; 11: 498-500
  • 51 Hofer IS, Mahoney B, Rebarber A. et al. An ex utero intrapartum treatment procedure in a patient with a family history of malignant hyperthermia. International journal of obstetric anesthesia 2013; 22: 146-148 doi:10.1016/j.ijoa.2012.12.009
  • 52 Foster RN, Boothroyd KP. Caesarean section in a complicated case of central core disease. Anaesthesia 2008; 63: 544-547 doi:10.1111/j.1365-2044.2007.05411.x
  • 53 Stoetzer C, Leffler A, Filitz J. Opioidgewöhnte Patienten – Perioperatives Management. Anästhesiol Intensivmed Notfallmed Schmerzther 2015; 50: 102-111 doi:10.1055/s-0041-100389
  • 54 Hay JL, White JM, Bochner F. et al. Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients. European journal of pain 2008; 12: 926-933 doi:10.1016/j.ejpain.2007.12.012
  • 55 Yang N, Zuo MZ, Yue Y. et al. Comparison of C(5)(0) for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in elderly and young patients. Chinese medical journal 2015; 128: 1994-1999 doi:10.4103/0366-6999.161338
  • 56 Shafer SL. The role of newer opioids in geriatric anesthesia. Acta anaesthesiologica Belgica 1998; 49: 91-103
  • 57 Radtke FM, Franck M, Lorenz M. et al. Remifentanil reduces the incidence of post-operative delirium. The Journal of international medical research 2010; 38: 1225-1232
  • 58 De Cosmo G, Sessa F, Fiorini F. et al. Effect of remifentanil and fentanyl on postoperative cognitive function and cytokines level in elderly patients undergoing major abdominal surgery. Journal of clinical anesthesia 2016; 35: 40-46 doi:10.1016/j.jclinane.2016.07.016
  • 59 Passot S, Molliex S. [Which doses of anaesthetic agents in centenarian patients? Interest of BIS monitoring]. Annales francaises dʼanesthesie et de reanimation 2005; 24: 814-817 doi:10.1016/j.annfar.2005.04.014
  • 60 Mercier FJ, Benhamou D. Promising non-narcotic analgesic techniques for labour. Bailliereʼs clinical obstetrics and gynaecology 1998; 12: 397-407
  • 61 Jones R, Pegrum A, Stacey RG. Patient-controlled analgesia using remifentanil in the parturient with thrombocytopaenia. Anaesthesia 1999; 54: 461-465
  • 62 Schnabel A, Hahn N, Muellenbach R. et al. Geburtshilfliche Analgesie in deutschen Kliniken – Remifentanil als Alternative zur Regionalanalgesie. Der Anaesthesist 2011; 60: 995-1001 doi:10.1007/s00101-011-1933-9
  • 63 DGGG. Off-Lable Use in Gynäkologie und Geburtshilfe: S1-Leitlinie AWMF-Leitlinie 015/057. 2013 Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/015-057l_S1_Off-Label-Use_in_Gynäkologie_und_Geburtshilfe_2013-03.pdf
  • 64 Freeman LM, Bloemenkamp KW, Franssen MT. et al. Patient controlled analgesia with remifentanil versus epidural analgesia in labour: randomised multicentre equivalence trial. Bmj 2015; 350: h846 doi:10.1136/bmj.h846
  • 65 Douma MR, Middeldorp JM, Verwey RA. et al. A randomised comparison of intravenous remifentanil patient-controlled analgesia with epidural ropivacaine/sufentanil during labour. International journal of obstetric anesthesia 2011; 20: 118-123 doi:10.1016/j.ijoa.2010.11.009
  • 66 Blair JM, Dobson GT, Hill DA. et al. Patient controlled analgesia for labour: a comparison of remifentanil with pethidine. Anaesthesia 2005; 60: 22-27 doi:10.1111/j.1365-2044.2004.03975.x
  • 67 Kranke P, Girard T, Lavandʼhomme P. et al. Must we press on until a young mother dies? Remifentanil patient controlled analgesia in labour may not be suited as a “poor manʼs epidural”. BMC pregnancy and childbirth 2013; 13: 139 doi:10.1186/1471-2393-13-139
  • 68 Heesen M, Klimek M. Obstetric analgesia – update 2016. Journal of perinatal medicine 2017; 45: 281-289 doi:10.1515/jpm-2016-0118
  • 69 Riphaus A, Wehrmann T, Weber B, Arnold J. et al. S3-Leilinie „Sedierung in der gastrointestinalen Endoskopie“. Z Gastroenterol 2008; 46: 1298-1330
  • 70 DGGG. S1-Leitlinie: Anwendung des CTG während Schwangerschaft und Geburt 08/2013. AWMF-Leitlinie 015/036. 2013 Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/015-036l_S1_CTG_Schwangerschaft_Geburt_2014-06.pdf
  • 71 Kostopanagiotou G, Markantonis SL, Polydorou M. et al. Recovery and cognitive function after fentanyl or remifentanil administration for carotid endarterectomy. Journal of clinical anesthesia 2005; 17: 16-20 doi:10.1016/j.jclinane.2004.03.008
  • 72 Ozkose Z, Yalcin Cok O, Tuncer B. et al. Comparison of hemodynamics, recovery profile, and early postoperative pain control and costs of remifentanil versus alfentanil-based total intravenous anesthesia (TIVA). Journal of clinical anesthesia 2002; 14: 161-168
  • 73 Fodale V, Schifilliti D, Pratico C. et al. Remifentanil and the brain. Acta anaesthesiologica Scandinavica 2008; 52: 319-326 doi:10.1111/j.1399-6576.2007.01566.x
  • 74 Lamperti M. Adult procedural sedation: an update. Current opinion in anaesthesiology 2015; 28: 662-667 doi:10.1097/ACO.0000000000000244
  • 75 Assmann A. Zusammenfassung der S3-Leitlinie „Sedierung in der gastrointestinalen Endoskopie“*. Anaesthesie und Intensivmedizin 2009; 176-181
  • 76 Garnier M, Bonnet F. Management of anesthetic emergencies and complications outside the operating room. Current opinion in anaesthesiology 2014; 27: 437-441 doi:10.1097/ACO.0000000000000088
  • 77 Rai MR, Parry TM, Dombrovskis A. et al. Remifentanil target-controlled infusion vs. propofol target-controlled infusion for conscious sedation for awake fibreoptic intubation: a double-blinded randomized controlled trial. British journal of anaesthesia 2008; 100: 125-130 doi:10.1093/bja/aem279
  • 78 Zhang X, He W, Wu X. et al. TCI remifentanil vs. TCI propofol for awake fiber-optic intubation with limited topical anesthesia. International journal of clinical pharmacology and therapeutics 2012; 50: 10-16
  • 79 Lallo A, Billard V, Bourgain JL. A comparison of propofol and remifentanil target-controlled infusions to facilitate fiberoptic nasotracheal intubation. Anesthesia and analgesia 2009; 108: 852-857 doi:10.1213/ane.0b013e318184eb31
  • 80 Cafiero T, Esposito F, Fraioli G. et al. Remifentanil-TCI and propofol-TCI for conscious sedation during fibreoptic intubation in the acromegalic patient. European journal of anaesthesiology 2008; 25: 670-674 doi:10.1017/S0265021508004195
  • 81 Liu HH, Zhou T, Wei JQ. et al. Comparison between remifentanil and dexmedetomidine for sedation during modified awake fiberoptic intubation. Experimental and therapeutic medicine 2015; 9: 1259-1264 doi:10.3892/etm.2015.2288
  • 82 Cattano D, Lam NC, Ferrario L. et al. Dexmedetomidine versus remifentanil for sedation during awake fiberoptic intubation. Anesthesiology research and practice 2012; 2012: 753107 doi:10.1155/2012/753107
  • 83 Hu R, Liu JX, Jiang H. Dexmedetomidine versus remifentanil sedation during awake fiberoptic nasotracheal intubation: a double-blinded randomized controlled trial. Journal of anesthesia 2013; 27: 211-217 doi:10.1007/s00540-012-1499-y
  • 84 Johnston KD, Rai MR. Conscious sedation for awake fibreoptic intubation: a review of the literature. Canadian journal of anaesthesia 2013; 60: 584-599 doi:10.1007/s12630-013-9915-9
  • 85 Wilhelm W, Dorscheid E, Schlaich N. et al. Remifentanil zur Analgosedierung von Intensivpatienten. Klinische Anwendung und erste Erfahrungen. Der Anaesthesist 1999; 48: 625-629
  • 86 Muellejans B, Matthey T, Scholpp J. et al. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial. Critical care 2006; 10: R91 doi:10.1186/cc4939
  • 87 Karabinis A, Mandragos K, Stergiopoulos S. et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Critical care 2004; 8: R268-R280 doi:10.1186/cc2896
  • 88 Breen D, Karabinis A, Malbrain M. et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial [ISRCTN47583497]. Critical care 2005; 9: R200-R210 doi:10.1186/cc3495
  • 89 Futier E, Chanques G, Cayot Constantin S. et al. Influence of opioid choice on mechanical ventilation duration and ICU length of stay. Minerva anestesiologica 2012; 78: 46-53
  • 90 Pandharipande P, Ely EW. Narcotic-based sedation regimens for critically ill mechanically ventilated patients. Critical care 2005; 9: 247-248 doi:10.1186/cc3523
  • 91 Minelli A, Abate M, Zampieri E. et al. Seizure adequacy markers and the prediction of electroconvulsive therapy response. The journal of ECT 2016; 32: 88-92 doi:10.1097/YCT.0000000000000274
  • 92 Dew RE, Kimball JN, Rosenquist PB. et al. Seizure length and clinical outcome in electroconvulsive therapy using methohexital or thiopental. The journal of ECT 2005; 21: 16-18
  • 93 Lalla FR, Milroy T. The current status of seizure duration in the practice of electroconvulsive therapy. Canadian journal of psychiatry Revue canadienne de psychiatrie 1996; 41: 299-304
  • 94 Ulusoy H, Cekic B, Besir A. et al. Sevoflurane/remifentanil versus propofol/remifentanil for electroconvulsive therapy: comparison of seizure duration and haemodynamic responses. The Journal of international medical research 2014; 42: 111-119 doi:10.1177/0300060513509036
  • 95 Dinwiddie SH, Glick DB, Goldman MB. The effect of propofol-remifentanil anesthesia on selected seizure quality indices in electroconvulsive therapy. Brain stimulation 2012; 5: 402-407 doi:10.1016/j.brs.2011.06.008
  • 96 Nishikawa K, Higuchi M, Kawagishi T. et al. Effect of divided supplementation of remifentanil on seizure duration and hemodynamic responses during electroconvulsive therapy under propofol anesthesia. Journal of anesthesia 2011; 25: 29-33 doi:10.1007/s00540-010-1049-4
  • 97 Lihua P, Su M, Ke W. et al. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. Cochrane database of systematic reviews 2014; (04) CD009763 DOI: 10.1002/14651858.CD009763.pub2.
  • 98 Galvez V, Tor PC, Bassa A. et al. Does remifentanil improve ECT seizure quality?. European archives of psychiatry and clinical neuroscience 2016; 266: 719-724 doi:10.1007/s00406-016-0690-9
  • 99 Chen ST. Remifentanil: a review of its use in electroconvulsive therapy. The journal of ECT 2011; 27: 323-327 doi:10.1097/YCT.0b013e31821072d2
  • 100 Hiddemann W. Medizin im Brennpunkt. Monographie. Berlin, Heidelberg, New York: Springer; 2000
  • 101 Sacchetti A, Jachowski J, Heisler J. et al. Remifentanil use in emergency department patients: initial experience. EMJ 2012; 29: 928-929 doi:10.1136/emermed-2011-200013
  • 102 Godwin SA, Burton JH, Gerardo CJ. et al. Clinical policy: procedural sedation and analgesia in the emergency department. Annals of emergency medicine 2014; 63: 247-258.e18 doi:10.1016/j.annemergmed.2013.10.015